The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.
NHF will update this page as more statements about product supply become available.
A statement from Dr. Valentino addressing the concerns of the community regarding the rapidly evolving COVID-19 situation.
The 2020 United Airlines Half Marathon has been cancelled due to concerns over transmission of COVID-19.
Due to the recommendations of local government, NHF's New York City staff will be working remotely until further notice. We will continue to work to serve the bleeding disorders community during this time.
Takeda responded to the HFA-NHF letter late yesterday regarding the recall of two lots of VONVENDI von Willebrand factor.
The National Hemophilia Foundation will continue to monitor the rapidly changing situation regarding COVID-19 and provide regular updates to our community.
XINITY® is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.
More than 400 people affected by bleeding disorders asked their legislators to take action on the Hemophilia SNF Access Act
We will provide updated guidance if new information has implication for the bleeding disorders community.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car